dual gip/glp-1 receptor agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Targeting GLP-1, GIP & GCG
Description
project administration, C.-S.W
doi: 10.1016/j.jdiacomp.2015.04.004
Can you talk about what those were and what you learned
Canada benefits from government price controls leading to lower patient costs, though some newer GLP-1s may be less accessible or require special authorization
The higher the dose of the GLP-1 agonist, the greater its effects
Multiorgan effect of GLP-1 agonists contributing to cardiovascualr benifits
